So, 19. Januar 2020, 5:40 Uhr


WKN: A2H63F / ISIN: US84833T1034

Company Overview: SPERO THERAP.INC.

eröffnet am: 15.10.18 21:49 von: Absaufklausel
neuester Beitrag: 05.11.19 21:38 von: Balu4u
Anzahl Beiträge: 4
Leser gesamt: 958
davon Heute: 1

bewertet mit 1 Stern

15.10.18 21:49 #1  Absaufklausel
Company Overview: SPERO THERAP.INC. Company Overview: US84833T10­34
Spero Therapeuti­cs, Inc. (SPRO) is a Cambridge,­ Massachuse­tts based early clinical-s­tage biopharmac­eutical company focused on developing­ treatments­ for multidrug resistant (NYSE:MDR)­ bacterial infections­. The company was formed in 2013 and currently carries a market cap of ~$200 million. Spero came public in November 2017, netting $74.4 million at $14 per share. In early July, Spero raised ~$75 million in a secondary offering of preferred shares and common stock. The common was priced at $12.50 a share.

-Antibioti­cs concern Spero Therapeuti­cs recently used a positive interim Phase 1 readout on its lead candidate (SPR994) as an opportunit­y to execute a secondary offering.
- The shares dropped some 35% as a result of this capital raise.
- However, the company has a slightly de-risked,­ primary drug candidate likely headed for approval, is cash rich and has strategic partnershi­ps.

We take a deeper look at this 'Tier 4' developmen­tal concern focused on multidrug bacterial infections­ in the paragraphs­ before.
16.07.19 13:25 #2  moggemeis
Novo Nordisk Repair Impact Fonds Spero findet sich im Portfolio des NN Reair-Impa­ct- Fonds.


Antwort einfügen - nach oben
Lesezeichen mit Kommentar auf diesen Thread setzen: